Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Gynecol Oncol. 2021 Feb 2;161(1):113–121. doi: 10.1016/j.ygyno.2021.01.025

Table 2:

Hazard ratios by TP53 mutational status on bevacizumab-containing arms (Arms 1 and 3) vs. the temsirolimus-containing arm (Arm 2).

Endpoint Group Point Estimate 95% Profile Likelihood Confidence Limits
PFS WT 0.87 0.58 1.31
Mutant 0.48 * 0.31 0.75
OS WT 1.05 0.64 1.77
Mutant 0.61 * 0.38 0.98

The number of patients in each arm and number events are provided in Supplementary Table I.

*

denotes statistically significant differences between groups; Arm 2 is the reference arm. WT: wild type TP53; mutant: mutation in TP53.